<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706923</url>
  </required_header>
  <id_info>
    <org_study_id>BCV-PA01</org_study_id>
    <nct_id>NCT04706923</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection</brief_title>
  <official_title>A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SymBio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SymBio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Dose from the safety and tolerability of&#xD;
      intravenous Brincidofovir (BCV, SyB V-1901) on multiple ascending doses in subjects with&#xD;
      Adenovirus infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IIa, open-label, multiple ascending dose confirmation, multicenter study to&#xD;
      evaluate the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) 0.2&#xD;
      mg/kg, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW (Cohorts 1 to 4) in adult and&#xD;
      pediatric subjects with AdV viremia. A total of 24 subjects aged 2 months and older will be&#xD;
      enrolled: 6 subjects to each Cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with BCV treatment-related adverse events as assessed by NCI CTCAE v5.0</measure>
    <time_frame>From initiation of BCV administration up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change AdV viremia in plasma measured from baseline up to 4 weeks</measure>
    <time_frame>From initiation of BCV administration up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Time-averaged [AdV AAUC] for AdV viremia in plasma from baseline up to 4 weeks</measure>
    <time_frame>From initiation of BCV administration up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak AdV viral load in plasma after onset of AdV viremia up to 4 weeks</measure>
    <time_frame>From initiation of BCV administration up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Adenovirus Infection</condition>
  <arm_group>
    <arm_group_label>BCV 0.2mg/kg BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCV 0.3mg/kg BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCV 0.4 mg/kg BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCV 0.4 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCV</intervention_name>
    <description>BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours</description>
    <arm_group_label>BCV 0.2mg/kg BIW</arm_group_label>
    <arm_group_label>BCV 0.3mg/kg BIW</arm_group_label>
    <arm_group_label>BCV 0.4 mg/kg BIW</arm_group_label>
    <arm_group_label>BCV 0.4 mg/kg QW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 2 months and older at the time of informed consent.&#xD;
&#xD;
          -  AdV DNA viremia &gt;10,000 copies/mL from a single sample, or 2 samples greater than 48&#xD;
             hours apart with the second result higher than the first and both greater than 1000&#xD;
             copies/mL, from the data obtained from the designated central virology laboratory of&#xD;
             the local laboratory using the blood sample(s) collected within 7 days prior to Day 1.&#xD;
&#xD;
          -  Either (a) have disseminated AdV disease or (b) have an underlying immunocompromised&#xD;
             state, and have asymptomatic AdV infection or localized AdV disease.&#xD;
&#xD;
          -  In the judgment of the investigator, be in a serious condition to be treated with&#xD;
             intravenous cidofovir for AdV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who weigh ≥120 kg.&#xD;
&#xD;
          -  NIH/NCI CTCAE (United States [US] National Institutes of Health [NIH]/National Cancer&#xD;
             Institute) Grade 2 or higher diarrhea (i.e., increase of ≥ 4 stools per day over usual&#xD;
             pre-transplant stool output) within 7 days prior to Day 1.&#xD;
&#xD;
          -  NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous&#xD;
             formation) within 7 days prior to Day 1.&#xD;
&#xD;
          -  NIH Stage 2 or higher acute GVHD of the liver function (i.e., bilirubin &gt;3 mg/dL [SI:&#xD;
             &gt;51 μmol/L]) within 7 days prior to Day 1.&#xD;
&#xD;
          -  NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea &gt;556 mL/m2/day for&#xD;
             pediatric subjects [or &gt;1000 mL/day for young adults as applicable, at centers in the&#xD;
             United States only], or severe abdominal pain with or without ileus) within 7 days&#xD;
             prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sayo Kobayashi</last_name>
    <phone>+81-3-6684-6616</phone>
    <email>MedInfo@symbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takeshi Yoshida</last_name>
    <phone>+81-3-6684-6616</phone>
    <email>MedInfo@symbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

